GlassScriptPhysician profile
Mudassar Asghar
NPI 1225101553
$4,120.29
in general payments reported to CMS, 2019-2025
39 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,603 · 2020: $501 · 2021: $664 · 2022: $658 · 2023: $546 · 2024: $27.55 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $693.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $896.34 | 2019-2023 | |
| Abbvie INC. | $540.03 | 2021-2024 | Ubrelvy, Qulipta, Duopa |
| Biogen, INC. | $241.77 | 2019-2023 | Vumerity |
| Lundbeck LLC | $169.75 | 2020-2025 | Vyepti |
| Emd Serono, INC. | $161.80 | 2019-2022 | |
| Amgen INC. | $139.88 | 2019-2020 | |
| Genzyme Corporation | $135.86 | 2019-2023 | |
| Allergan, INC. | $133.24 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $131.56 | 2019-2020 | |
| Ucb, INC. | $125.68 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $125.36 | 2021 | |
| Genentech USA, INC. | $125.00 | 2019 | |
| Assertio Therapeutics, INC. | $124.13 | 2019 | |
| Adamas Pharmaceuticals, INC. | $123.42 | 2019 | |
| Penumbra, INC. | $96.71 | 2019 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mudassar Asghar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.